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ABSTRACT 
The high prevalence of the risk factors for Non-Alcoholic Fatty Liver Disease (NAFLD) made it one of the most common non-
communicable diseases with high morbidity, nationally and worldwide. Early pathogenic implication of cellular hypoxia in 
Asymptomatic Simple Non-Alcoholic Isolated Hepatosteatosis (ANIHS) was investigated in this cross-sectional study and 
correlated changes in systemic hypoxia biomarkers with body mass index (BMI) in apparently healthy ANIHS participants with 
normal liver enzymes and size. We enrolled 180 adult consented volunteering Saudi participants in the period from January 1 to 
June 1, 2019. They comprised of normal lean healthy controls (n = 40; BMI = 18.5-25) and ANIHS participants (n 140) that were 
subdivided as overweight (n = 64; BMI = 25.1 – 30) and obese (n = 76; BMI >30 - <40). Male/female ratio was 1:1 and age 
range was 24 – 50 years (37.0 ± 7.85) without significant differences among groups. The cellular hypoxia biomarkers; lactate, 
pyruvate, lactate: pyruvate (L/P) ratio & hypoxia inducible factor (HIF)-1α were estimated in fasting plasma. Lactate was 
significantly higher in obese ANIHS compared to each of overweight ANSHS participants and controls. Pyruvate was 
significantly lowest in overweight ANIHS followed by obese ANIHS participants - compared to highest level in controls. L/P 
ratio was highest in obese ANIHS followed by overweight ANIHS participants, compared to controls. HIF-1α was more than 3-
folds higher in obese ANIHS participants compared to healthy controls, with a mild increase in overweight ANIHS participants. 
Pyruvate and the ratio were significantly connected to steatosis, whereas lactate and HIF-1α were significantly connected to both 
BMI and hepatosteatosis. Cellular hypoxic changes may be implicated in pathogenesis of ANIHS. Plasma HIF-1α level reflects 
the correlation between BMI and occurrence/progression of ANIHS. Cellular hypoxia with responsive increases in HIF-1α could 
be prognostically good provided that it correlates a cytoprotective functional transcriptional response. 
Keywords: Non-alcoholic fatty liver, isolated hepatic steatosis, obesity, cellular hypoxia biomarkers, lactate, pyruvate, lactate-pyruvate ratio, 
hypoxia-inducible factor-1 alpha. 
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INTRODUCTION 
 
Overweight and obesity reached a pandemic level worldwide, 
with a consequent significant increase in the incidence of 
metabolic syndrome, insulin resistance, diabetes, non-
alcoholic fatty liver disease (NAFLD) and coronary heart 
disease. Obesity is a chronic low grade inflammatory status. 
Adipocytic hypertrophy accompanied with cellular hypoxia, 
lipids toxicity and endoplasmic reticulum stress lead to 
adipokine dysfunction. Hypoxia-induced increase in vascular 
permeability with enhanced immune cell infiltration and 
release of inflammatory effectors establish a proinflammatory 
milieu (Santareno et al. 2008; Cheng et al., 2018; Engin, 2017; 
Zhou et al., 2017). In such a state, the already low vascularized 
adipose tissue became more hypoxic (Santareno et al. 2008). 
To a great extent, this hypoxia is due to the expanded size of 
adipocytes, diminished adipose tissue vascularization and 
elevated fatty acid metabolism that exhaust oxygen (Pasarica 
et al., 2009).  
 Abnormal accumulation of lipids, mainly triglycerides, in 
hepatocytes accompanies onset of obesity. Lipid accumulation 
badly affects hepatocytes in a progressive course spanning 
simple reversible/irreversible steatosis, steatohepatitis, 
cirrhosis, to hepatocellular carcinoma and death (Guerrero et 
al., 2009; Younossi, 2019). The non-alcoholic form of the 
fatty liver disease - NAFLD - is one of the most common liver 
diseases that affect around 25-35% of the population 
worldwide. It has a high rate of morbidity and mortality as it 
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is a main cause of chronic liver disease and transplantation. 
The industrialized world with high rate of obesity, diabetes 
mellitus, and metabolic syndrome observed the surge first. 
However, improvement in living standards and obesogenic 
changes in lifestyle and dietary habits induced a serious rapid 
rise in prevalence of NAFLD in developing countries, as well 
(Chalasani et al., 2018; Mantovani et al., 2018; Li et al., 
2019). The prevalence of NAFLD in Saudi Arabia is strongly 
associated with known risk factors that include the obesity 
epidemic, diabetes mellitus, metabolic syndrome, 
hyperlipidemia and drug misuse (Akbar and Kawther, 2003; 
Al-Nozha et al., 2005).  
 The gluconeogenic function of liver clears up to 70% of 
blood lactate (Phypers and Pierce, 2006). Under hypoxic 
conditions, this burden increases proportion to lactate 
production, and, become worse in case hepatocytes 
themselves become hypoxic. Any degree of hepatic 
dysfunction, as in obesity and NAFLD, instigates lactate 
accumulation (Van Hall, 2010). Proportionation with pyruvate 
depends on the source of lactate; hypoxic vs. non-hypoxic 
(Suistomaa et al., 2000). Organisms are adapted to the 
changeable oxygen level via developing multiple oxygen-
sensitive systems that maintains oxygen homeostasis. Major 
orchestrator of the hypoxic cellular response is the 
heterodimeric hypoxia-inducible transcription factors (HIFs)-
1 and -2 (Roth and Copple, 2015). Glucose transporters, 
glycolytic enzymes, pyruvate dehydrogenase kinase-1 and 
insulin receptor substrate-2 are HIF-1-responsive genes. 
Oppositely, HIF-1α lowers the expression of key regulatory 
enzymes of fatty acid synthesis and de novo lipid synthesis, 
reduces serum cholesterol levels, and, protected against 
hepatic steatosis in mice (Rahtu-Korpela et al., 2014). 
Upregulation of HIF-2α protects hepatocytes from hypoxia-
induced oxidative stress and apoptosis, and doweregulates the 
expression of pro-fibrogenic mediators (Liu J et al., 2017). 
Experimental hypoxia and lead toxicity-induced liver damage 
is correlated with massive increases in serum HIF-1α levels 
(Das et al., 2015). Enhancement of HIF-1α activity in mice by 
knockdown or chemical inhibition of its hydroxylase prevents 
high-fat diet-induced adiposity and adipose tissue 
inflammation, and, improved glucose tolerance and insulin 
sensitivity. In chronic hypoxia, increases in HIF-1α are due to 
its salvage from ubiquitin-dependent degradation and 
translocation into the nucleus, where it activates the hypoxia 
response element (HRE). The latter decreases T-regulatory 
cells and release of anti-inflammatory cytokines (IL-10, IL-
35, TGF-β), while increasing T-helper cells and 
proinflammatory cytokines (NF-κB, IL-6, and IL-17) (Liu Z 
et al., 2018). Increased expression of HIF-1α induced by 
chronic hypoxia activates the fibrogenic enzyme lysyl 
oxidase. The anti-steatotic metformin induced lactic acidosis 
could reflect an effect of HIF-1α orchestrated processes (Han 
et al., 2019).   
 We were the 1st worldwide to characterize the changes in 
circulating levels in HIF-1α as a disease biomarker (Hamed et 
al., 2012; Elsayh et al., 2014). The target of this study was to 
investigate the changes in circulating levels of cellular 
hypoxia biomarkers (lactate, pyruvate, lactate/pyruvate ratio 
and HIF-1α) in apparently healthy, overweight and obese 
Saudi participants with simple/isolated hepatosteatosis 
compared to lean healthy controls. Correlations among these 
biomarkers stratified to the body mass index (BMI) were 
assessed. This illustrates the early implication of cellular 
hypoxia in the pathogenesis of fatty liver disease.  
 
MATERIAL AND METHODS   
Participants and Setting: The present cross-sectional study 
anonymously enrolled 180 adult consented Saudi volunteering 
participants. Participants were randomly selected by simple 
consequent inclusion from Sakaka community personnel, 
referred to undergo routine health checkup at a private Poly-
Clinic Center, Sakaka, Aljouf, Saudi Arabia, in the period 
from January 1 to June 1, 2019. They comprised lean healthy 
Controls [body mass index ((BMI) = 18.5 – 25 kg/m2; n = 40), 
and, apparently healthy participants with asymptomatic non-
alcoholic isolated hepatosteatosis (ANIHS). The latter group 
was subdivided into overweight ANIHS (n = 64; BMI = 25.1 
– 30 kg/m2) and obese ANIHS (n = 76; BMI >30 - <40 kg/m2) 
participants. Their male/female ratio was 1:1. Their age 
ranged from 24 – 50 years (37.0 ± 7.85) without statistically 
significant differences among groups or within each group 
(male/female) considering the age. Fatty liver participants 
with increased liver size or increased hepatocyte integrity 
biomarkers were excluded. None of our participants is on 
specific medication and none of them qualify to have 
metabolic syndrome as defined by National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III (ATP 
III) and later updates. Alcoholics and those with fatty liver 
disease due to drug exposure and abuse, pregnancy, viral 
hepatitis, autoimmune hepatitis, primary biliary cirrhosis, 
diabetes, thyroid disease and hemochromatosis, hypertensive 
and those on dieting regimens were excluded. Participants 
were free of Helicobacter pylori (serology and fecal antigen 
negative) and other chronic metabolic, autoimmune, 
endocrine, and renal diseases. Following the tenets of the 
Declaration of Helsinki, each participant signed a written 
informed consent and the study was approved by Jouf 
University Bioethical Committee (Approval # 9-15-9/40).    
 
ANIHS Assessment and BMI measurement: According to 
the international scanning guidance and protocol, simple 
hepatosteatosis was transabdominal ultrasonographically 
characterized by a single independent consultant radiologist. 
Only patients with normal liver enzymes and normal liver size 
were included in this study. Normal hepatocyte 
function/integrity (measured as serum AST, ALT, AST/ALT 
ratio, LDH, alkaline phosphatase, γ-glutamyl transpeptidase, 
indirect, direct, and total bilirubin, glucose, prothrombin time, 
and, albumin and globulin and their ratio along with lipid 
profile) and increased parenchymal real-time ultrasonographic 
echogenicity were used for diagnosing simple fatty liver in our 
≥10-hour overnight fasting participants as previously 
described for the same cohort of patients (Elasbali et al., 
2020). Hepatic steatosis index (HSI) calculated as 8 × 
ALT/AST + BMI (+2, if female; +2, if diabetes mellitus; that 
does not apply here) was used to substantiate the 
ultrasonography; giving a score between 30 and 36 (Lee et al., 
2010). 
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Biochemical markers analysis: Fasting peripheral blood 
samples of 2.5 mL were collected on EDTA from each 
participant, and, plasma was recovered, and aliquot stored at -
70 oC until used. Specific ELISA kit from Cloud-Clone Corp. 
(Wuhan, Hubei, PRC; cat# SEA798Hu) was used to measure 
human HIF-1α level. Lactate and pyruvate were measured 
using quantitative enzymatic colorimetric assay kits in plasma 
aliquots immediately deproteinized by perchloric acid (cat# 
MAK064 and MAK071; Sigma-Aldrich Co., St. Louis, MO, 
USA) and lactate: pyruvate (L/P) ratio was calculated.    
 
Statistical analysis: Statistical analysis was conducted using 
SPSS version 23.0 (IBM Corp. IBM SPSS Statistics for 
Windows. Armonk, NY). Continuous variables were 
expressed as mean ± standard deviation (SD) and median ± 
Interquartile range (IQR) in case of non-normal distribution. 
Normal distribution of variables was checked by Shapirowilk 
W-test, where, a significant W-test means non-normal 
distribution. Variables with normal distribution were 
compared with analysis of variance (ANOVA) test and 
independent samples t-test. Intragroup correlation among 
variables was assessed by Pearson or Spearman correlation 
coefficient test. Variables with asymmetric distribution were 
analyzed by Kruskal-Wallis and Mann-Whitney U tests. ROC 
analysis was carried out assuming nonparametric distribution. 
P value <0.05 was considered significant. 
 
RESULTS   
In this study, we observed that there is significant difference 
in plasma lactate levels comparing healthy controls (1.5 ± 0.7 
mg/dL) and otherwise healthy asymptomatic ANIHS 
participants (1.8 ± 0.9 mg/dL; P = 0.001). Lactate was highest 
in obese ANIHS participants (2.1 ± 1 mg/dL), followed by 
overweight ANIHS participants (1.7 ± 0.9 mg/dL) vs. the 
lowest level in controls. This revealed significantly higher 
plasma lactate level in obese vs. each of controls and 
overweight ANIHS participants (p ˂0.003 and ˂0.027, 
respectively), while the level was non-significantly different 
comparing controls and overweight heptosteatotic group. 
Similar significant changes were observed for other plasma 
hypoxia biomarkers; pyruvate (3.91 ± 2.73 vs. 2.938 ± 2.504 
mg/dL), L/P ratio (0.86 ± 1.29 vs. 1.946 ± 2.51) and HIF-1α 
(221.05 ± 223.95 vs. 522.81 ± 1235.67 pg/dL) comparing 
controls and heptosteatotic participants (P = 0.01, = 0.001 and 
˂0.001, respectively). This revealed a significant difference in 
pyruvate level only comparing controls vs. overweight 
ANIHS persons (2.49 ± 2.54 mg/dL; P = 0.013), but 
nonsignificant difference for obese ANIHS (2.804 ± 2.22 
mg/dL) vs. each of controls and overweight ANIHS persons 
(P = 0.058 and = 0.732). L/P ratio was nonsignificantly 
different comparing overweight ANIHS (2.01 ± 2.03) vs. each 
of controls (P = 0.055) and obese steatotic participants (2.465 
± 3.15; P = 0.521), but significant difference comparing 
controls and obese steatotics (P = 0.003). Similar pattern was 
evident for HIF-1α, with nonsignificant differences 
comparing overweight ANIHS (350.96 ± 381.28 pg/dL) vs. 
each of controls (P = 0.856) and obese steatotics (826.34 ± 
1824.50 pg/dL; P = 0.057), but significant difference 
comparing controls and obese steatotics (p = 0.031). These 
differences in plasma levels of hypoxia biomarkers implicate 
an early involvement of cellular hypoxia in ANIHS with 
overweight/obesity, and, may explain the higher comorbid 
cardiometabolic events among them. 
 Correlation among parameters within healthy lean 
controls showed significant positive correlations between 
plasma lactate vs. L/P ratio (P/r =; 0.001/0.516), pyruvate vs. 
HIF-1α (0.011/0.363), while, L/P ratio negatively 
significantly correlated with each of plasma pyruvate (0.001/-
0.830) and HIF-1α (0.05/-0.281). Among overweight 
steatotics, lactate significantly positively correlated with each 
of L/P ratio (0.001/0.411) and HIF-1α (0.041/0.219), and, 
plasma pyruvate level significantly negatively correlated with 
plasma L/P ratio (0.001/-0.934). Among obese steatotic 
participants, significant positive correlations were evident 
between plasma lactate vs. L/P ratio (0.001/0.517), and 
pyruvate vs. HIF-1α (0.05/0.258), while L/P ratio significantly 
negatively correlated vs. each of pyruvate (0.001/-0.871) and 
HIF-1α (0.05/ -0.249). 
 To determine whether the differences in plasma hypoxia 
biomarkers among patients with and without simple non-
alcoholic hepatosteatosis can be attributed to obesity alone or 
not, we compared the plasma levels of lactate, pyruvate, their 
ratio and HIF-1α in overweight and obese ANIHS groups 
(Table 2). It was found that lactate and HIF-1α are 
significantly different comparing overweight and obese 
steatotic participants (P = 0.01 and = 0.004, respectively), 
while pyruvate and L/P ratio were statistically non-different. 
Given the fact that they all are higher than healthy lean 
controls, these results implicate that among the four plasma 
hypoxia biomarkers utilized, pyruvate and L/P ratio are more 
specific for hypoxic injury related to ANSHS. Distinctively, 
lactate and HIF-1α are more sensitive to the combined effect 
of obesity and ANIHS.
Table 1: 
 Comparison of the levels of the investigated plasma hypoxia biomarkers among adult lean healthy controls (Controls; n = 40), and, overweight 
(OW-SHS; n = 64) and obese (O-SHS; n = 76) participants with simple non-alcoholic hepatosteatosis (SHS).  
Parameter Controls OW-SHS O-SHS All SHS (n = 140) X2 (P) 




3.91 ± 2.73 (3.45 ± 
3.6) 
2.49 ± 2.54 (1.27 ± 
3.5) 
2.804 ± 2.22 (3.091 ± 
4.4) 




Pyruvate Ratio  
0.86 ± 1.29 
(0.35 ± 0.7) 
2.01 ± 2.03 
(1.278 ± 2.7) 
2.465 ± 3.15 
(0.864 ± 4) 
1.946 ± 2.51 




Factor 1α, pg/mL 
221.05 ± 223.95 
(154.88 ± 105.8) 
350.96 ± 381.28 
(218.97 ± 132.2) 
826.34 ± 1824.50 
(256.382 ± 210.2) 
522.81 ± 1235.67 
(215.669 ± 146.9) 
35.96 
(<0.001) 
Data shown are mean ± SD (Median ± IQR), and X2 (P) Kruskal Wallis test. Shapiro Wilk Test (W-test) was significant for all 4 parameters 
(asymmetrical distribution). 
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 In this study, we measured area under curve to dig deep 
into the differentiation power of four plasma hypoxia 
biomarkers (Table 3 and Figure 1). All four markers, i.e., 
lactate, pyruvate, L/P ratio and HIF-1α can differentiate 
significantly between cases and controls, but the best one was 
HIF-1α. Higher levels of HIF-1α and lactate were significantly 
associated with ANIHS and higher BMI. However, pyruvate 
and L/P ratio failed to differentiate between overweight and 
obese participants with ANIHS. This confirms our other 
finding that pyruvate and L/P ratio are more specific for 
hypoxic injury related to ANIHS. 
 
Table 2: 
Distribution of the plasma hypoxia parameters among overweight 
(OW; n = 64) vs. obese (O; n = 76) individuals with simple non-
alcoholic hepatosteatosis (SHS).  
Parameter OW-SHS O-SHS P 
Lactate, mg/dL 60.91 (3898.0) 78.58 (5972.0) 0.010 
Pyruvate, mg/dL 67.16 (4298.0) 73.32 (5572.0) 0.365 
Lactate to Pyruvate 
Ratio 
70.19 (4492.0) 70.76 (5378.0) 0.933 
Hypoxia-inducible 
Factor 1α, pg/dL 
59.72 (3822.0) 79.58 (6048.0) 0.004 




Although simple/isolated hepatosteatosis is viewed as a mild 
reversible issue, it has morbid ramifications to the liver as it 
becomes liable to inflammation, fibrosis, cirrhosis and cancer. 
This mandates its prevention, early diagnosis and treatment. 
NAFLD is a major cause of liver-related and cardiometabolic 
morbidity and mortality worldwide not only in obese, diabetic, 
and dyslipidemic but also increasingly in normal-weight 
individuals. The multifaceted initiation and progression of the 
disease encompass modulation of the metabolism of glucose, 
lipid, and bile acids, inflammation, apoptosis, and fibrosis 
(Paik et al., 2019). This necessitates a complex interaction 
among environmental factors (i.e., Western diet and fast 
foods), obesity, insulin resistance, and changes in microbiota, 
with predisposing genetic variants. They all disturb lipid 
homeostasis with a toxic accumulation of triglycerides and 
other lipid species in hepatocyte. The latter exhibits 
endoplasmic reticulum stress, disturbed autophagy, and, 
ultimately, hepatocyte injury and death. This triggers hepatic 
inflammation, hepatic stellate cell activation, and progressive 
fibrogenesis that entails liver transplant (Arab et al., 2018).  
 HIF-1α is a highly conserved transcription factor that 
plays a key role in tissue response to hypoxia. Obese adipose 
tissue is glucose intolerant, inflammatory and hypoxic. This 
hypoxic milieu, due to imbalance between the metabolic 
demand and oxygen supply, have a crucial role in initiating 
many obesity-related disorders by abnormal expression of 
multiple genes in adipocytes (Mazzatti et al., 2012) - in 
particular a high expression of HIF-1α. 
 Adipocyte-specific knockout of HIF-1α, in mice, reverses 
all of these disorders, prevent liver fibrosis, and enhanced 
postprandial insulin secretion and increased serum level of 
each of glucagon-like peptide (GLP)-1 and adiponectin 
(Mesarwi et al., 2016; Kihira et al., 2014).These consequences 
highlight the crucial role of HIF‐1α in the development of liver 
fibrosis in NAFLD patients. In our participants, a reciprocal 
relationship was evident between the induced HIF-1α and our 
previous reported reduction in circulating levels of GLP-1 for 
the same cohort (Elasbali et al., 2020).
 
Table 3: 
 Area under receiver operating characteristic (ROC) curve (AUC) for differentiation between overweight vs. obese simple non-alcoholic 
hepatosteatosis cases (SHS; n = 140), and them vs. lean healthy controls (n = 40).  
Parameter SHS Cases vs. Controls Overweight vs. Obese SHS 
AUC (95% CI) P AUC (95% CI) P 
Lactate, mg/dL 0.642 (0.542 to 0.742) 0.006 0.626 (0.532 to 0.721) 0.010 
Pyruvate, mg/dL 0.354 (0.264 to 0.444) 0.005 0.544 (0.447 to 0.641) 0.371 
Lactate to Pyruvate Ratio 0.697 (0.609 to 0.785) <0.001 0.504 (0.406 to 0.602) 0.933 
Hypoxia-inducible Factor 1α, pg/dL 0.781 (0.684 to 0.878) <0.001 0.642 (0.548 to 0.735) 0.004 
Data shown are AUC (95% CI) and p values. 
    
 
 
Figure 1.  
Left: Area under receiver 
operating characteristic (ROC) 
curve (AUC) for differentiation 
between overweight/obese 
simple non-alcoholic 
hepatosteatosis cases (n = 140) 
and lean healthy controls (n = 
40). Right: AUC for variance in 
the measured hypoxia biomarkers 
vs. obesity in obese cases with 
simple non-alcoholic 
hepatosteatosis cases (n = 76). 
For detailed data and p value, see 
Table 3. Diagonal segments are 
produced by ties. 
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Our observation of a progressive increase in level of plasma 
HIF-1α and L/P ratio with the rise in body weight is in 
agreement with the results reported by Golzar et al. (2019) 
showing increased expression of HIF-1α in adipose tissue of 
mice given high fat diet for 9 weeks. This may be explained 
by expansion of adipose tissue with inadequate compensatory 
blood supply to hypertrophic adipocytes resulting in local 
hypoxia (Ludzki et al., 2018). Increased HIF-1α expression in 
obese adipose tissue induces a potent profibrotic 
transcriptional program leading to fibrosis and induces the 
obesity-associated inflammation - through recruiting M1-
macrophages that secrete proinflammatory cytokines and 
connective tissue growth factor (Warbrick and Rabkin, 2019). 
Similar to our findings, at the onset of obesity, increases in 
blood free fatty acids prompt increases in concentrations of 
lactate and HIF-1α and replace the beneficial gut microbiota 
with harmful proinflammatory lipopolysacchide-secreting 
microbiota (Dai and Wang, 2015). The free fatty acids-
induced HIF-1α is due to blockage of succinate 
dehydrogenase. Accumulation of succinate induces the 
synthesis of HIF-1α. The latter increases activities of 
hexokinase, phosphofructokinase, and lactate dehydrogenase, 
and, inhibits pyruvate dehydrogenase. This leads to slower 
oxidative phosphorylation and increased lactate production. 
Also, the state of hypoxia associated with obesity augments 
glucose fermentation with higher lactate production than 
normal cells (Ray et al., 2018). Moreover, The 
hepatoprotective anti-steatotic oroxylin A flavonoid prevents 
nuclear translocation of HIF-1α, while activation of HIF-1α 
attenuates the effect of oroxylin A on lipid droplets 
accumulation and genes related to lipid metabolism in vitro 
and in vivo (Shen et al., 2016). Specific inhibition of HIF-1α 
by 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole alleviates 
hepatosteatosis and inflammation with reduced NF-κB 
expression and reduced liver fibrosis degree in a rat model of 
non-alcoholic fat liver diseases (Jin et al., 2018).  
 Other than quality control factors, high blood lactate 
could be due to primary and secondary mitochondrial 
dysfunction, tissue hypoxia/ischemia, or specific vitamin 
deficiency. L:P molar ratio reflects lactase dehydrogenase 
product and substrate equilibrium and is indirectly mirrored as 
cytoplasmic NADH:NAD+ ratio that is controlled by cellular 
respiration. The extent of dysfunction of the latter 
proportionally correlates elevation of L:P molar ratio (Lane et 
al., 2016). The progressive increase in plasma lactate, L/P 
ratio & HIF-1α found in the present study in asymptomatic 
otherwise healthy overweight and obese ANIHS participants 
was confirmed by significant positive correlations among 
lactate & L/P ratio in the 3 studied groups & between lactate 
and HIF-1α in overweight steatotic participants. The elevated 
plasma lactate level associated with high L/P ratio are similar 
to results of a study done by Moon et al. (2017) on rats fed 
high fat diet for 6 weeks - indicating enhancement of 
anaerobic glycolysis. This may be the result of impaired 
hepatic glucose production & impaired gluconeogenesis, as 
lactate is the major substrate for this process - at the expense 
of elevated hepatic lipid synthesis. Besides, the increased 
adipose tissue mass, associated with obesity, augments plasma 
lactate level - as adipose tissue is a major source of lactate 
reflecting up-regulated anaerobic glycolysis (Xie et al., 2012). 
It is worth noting that, utilizing several molecular 
mechanisms, accumulation of lactate is immunosuppressive – 
a phenomenon ascribed to chronic liver illness (Comito et al., 
2019; Heymann and Tacke, 2016). With NAFLD as the 
instigator, HIF-1α is implicated in hepatocellular 
carcinogenesis, aggression and progression (Wang et al., 
2017; Liu Z et al., 2017; Liu Z et al., 2018; Dou et al., 2019). 
In this concern, we observed a connection between changes in 
plasma lactate and HIF-1α with both of ANSHS and changes 
in BMI, whereas, changes in pyruvate and L/P ratio was 
connected to ANIHS only. 
 Although we reviewed about 900 individuals, due to our 
stringent exclusion criteria, we enroll except the presented 
number of participants. We know that liver biopsy 
histopathological analysis is the standard diagnostic approach 
for grading hepatosteatosis, fibrosis and/or inflammation. 
However, nobody would resort to that it would be indicated or 
accepted by participants in a setting like ours; needless to 
mention its inherent complications. The other alternatives, 
magnetic resonance spectroscopy and 2D-SWE ultrasound 
elastography, were not available for our use. Although we 
excluded morbid obese participants, with criteria used for 
characterizing simple/isolated hepatosteatosis, still we could 
have missed participants with low degree of steatosis. Since 
we excluded participants with diabetes or prediabetes, we did 
not correlate our finding with insulin resistance.    
 In conclusions, there is an early induction of cellular 
hypoxia in apparently healthy overweight and obese Saudi 
participant with ANIHS – measured as plasma lactate and 
HIF-1α. In this context, HIF-1α is an attractive druggable 
target that could ameliorate the early course of the disease 
when controlled. Such pathogenetic link among cellular 
hypoxia, BMI and hepatosteatosis requires further dissection 
utilizing multicenteric longitudinal studies with specific anti-
hepatosteatotic treatment and/or HIF-1α-blocking 
intervention – that would confirm a causal relationship. 
Moreover, circulating levels of HIF-1α could be characterized 
as a prognostic/diagnostic biomarker for ANIHS in 
conjunction with obesity.  
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